168 results found | searching for "Disorder"

2 3 4 5 6 7 8 9 10 Next Last 
  • jameshebrew
  • PRESENTLY, MORE THAN 100 PLAYERS ACROSS THE GLOBE CLAIM TO OFFER NUTRIGENOMICS TESTS / SERVICES BASED ON GENETIC ASSESSMENT Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advances in DNA sequencing technologies have enabled significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Further, the success of the Human Genome Project, which mapped the whole human DNA, has paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the nutrigenomics market, over the coming 13 years. We have provided informed estimates of the likely evolution of the nutrigenomics market in the short to mid-term and long term, for the period 2022-2035. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html Presently, extensive studies are being conducted to understand the interaction between nutrients and gene expression at the molecular level to determine effect of a specific nutrient and dietary regime on the human health. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings. Further, the growing interest in nutrigenomics is supported by the rising awareness about the influence of diet on human health and its potential with respect to minimizing the risk of various diet-related diseases, including diabetes, cardiovascular disorders, chronic respiratory diseases and oncological disorders. It is worth mentioning that there are several companies that provide nutrigenomic test offerings directly to consumer, through availability of online genetic test kits and at-home sample collection facilities. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. This field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. In this context, in the past 3 years, over 135 nutrigenomics focused research articles have been published, highlighting the active initiatives of researchers to illustrate the effect of nutrition on regulation of gene expression. At present, there are some ethical and regulatory challenges associated with nutrigenomics, including the potential misuse of personal data, as well as uncertainty related to genetic phenotypic predispositions, for conditions where no proven treatment exists. However, the benefits offered by nutrigenomics outweigh the uncertainty associated with its adoption. Considering the growing focus on personalized diets and active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future. For additional details, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • Mubazgmi2
  • Adhesion Barrier Market reached USD 695 million in 2020 and will grow at 7.9% CAGR during 2021-2028 | Size, Industry Report & Forecast The factors driving the growth of Adhesion Barrier Market includes rise in the number of trauma care centers around the world, increasing prevalence of gynecological disorders and neurological disorders around the world and growing awareness about adhesion formation For more info: https://www.marketwatch.com/press-release/adhesion-barrier-market-reached-usd-695-million-in-2020-and-will-grow-at-79-cagr-during-2021-2028-size-industry-report-forecast-2022-09-16 [more]
  • bhartieyefoundation8
  • A refractive error is a very common eye disorder, it occurs when the eye cannot clearly focus the images from the outside world at the back of the eye. read more: https://rotf.lol/293n77jk [more]
  • jameshebrew
  • The precision medicine software developers market is projected to grow at an annualized rate of 30%, till 2032, claims Roots Analysis Given their ability to cater to the existing unmet needs in the healthcare sector, various industry stakeholders have made investments for the development and implementation of precision medicine software applications for diagnosis, analysis and treatment of a range of disorders. Roots Analysis has announced the addition of “Precision Medicine Software Market 2021-2032” report to its list of offerings. Conventional methods being used for the treatment of various disease indications are fraught with several challenges, including inefficiency of reporting any medical symptom / condition at the initial stage, frequent visits to hospitals, the one-size-fits-all approach. These bottlenecks have encouraged healthcare professionals to shift their attention towards the use of precision medicine software applications. Key Market Insights 125+ precision medicine software applications are currently available / under development This segment of the industry is dominated by the presence of small players ( [more]
  • justinhanger12
  • https://redcliffelabs.com/delhi/tests/thyroid-test We at Redcliffe Labs provide a thyroid test with free home sample collection. The thyroid profile test is usually high, but with Redcliffe Labs, you can get an affordable thyroid test at home including T3 test, T4 test and TSH test with assured safety and accurate results the following day. This thyroid function test includes 3 parameters in a single report which aids in diagnosing thyroid disorders Request a callback with us and schedule a thyroid antibody test. Discover the cost and book a thyroid test online from Redcliffe Labs.
  • plemenpol
  • If the weather's getting you down, boost your mood with some serotonin rich bananas or Brazil nuts. Some 30% of cases of loss of Libido Boosting are caused by depression and Seasonal Affective Disorder. OFFICIAL WEB:-https://kitcoben.com/libido-boosting-gum-mies/
  • jameshebrew
  • The human microbiome market is anticipated to grow at a CAGR of 24% till 2035, claims Roots Analysis With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications. Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings. The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Key Market Insights Over 230 drug candidates are currently being developed by more than 70 drug developers Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders. More than 75 diagnostics and screening / profiling test are available / under development Of these, around 80% of the tests are available in the market, while rest are under development. More than 40 companies are engaged in providing these tests; these are primarily based in North America (45%) and Europe (39%). It is worth highlighting that majority (68%) of the players are small companies. FMTs are the only commercially available microbiome therapies approved by the FDA These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications. Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period. More than USD 1 billion has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million. Outsourcing has become an integral part of the microbiome and live biotherapeutics development process Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe. Microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035 As late-stage therapeutics will get approved by the FDA in the foreseen future, the microbiome therapeutics market is likely to grow at an annualized rate of 37% till 2035. It is worth mentioning that microbiome diagnostics is likely to capture 20% of the total microbiome market share by 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/281/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of microbiome therapeutics?  Which are the key microbiome based drugs being developed across various stages of development?  Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?  Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?  Which types of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in the field of human microbiome therapeutics and diagnostics?  What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?  What is the role of various start-ups engaged in developing human microbiome therapeutics?  Which are the most commonly targeted therapeutic indications for which microbiome therapeutics are being developed?  What are the various steps involved in the manufacturing of microbiome therapeutics?  What are the key considerations for selecting a CMO / CRO for manufacturing of microbiome therapeutics?  What are the various algorithms / tools used to analyze data generated from microbiome research?  How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?  What are the various non-pharma applications of microbiome products? The financial opportunity within the human microbiome therapeutics market has been analyzed across the following segments:  Type of Product  Probiotic Drugs  Other Drugs  Target Indication  Recurrent C. difficile Infection  Necrotizing Enterocolitis  Primary Hyperoxaluria  Graft versus Host Disease  Therapeutic Area  Infectious Diseases  Digestive and GI Disorders  Rare Disorders  Route of Administration  Oral Route  Rectal Route  Type of Formulation  Capsules  Suspensions  Enemas  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the human microbiome diagnostics and screening / profiling tests market has been analyzed across the following segments:  Target Indication  Irritable Bowel Syndrome  Inflammatory Bowel Disease  Colorectal Cancer  Diabetes Mellitus  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the fecal microbiota therapies market has been analyzed across the following segments:  Key Geographical Regions  North America  Europe  Asia Pacific The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the human microbiome market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms, including:  Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)  Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)  Alicia Scheffer (Chief Executive Officer, Floragraph)  Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)  Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)  Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)  Assaf Oron (Chief Business Officer, BiomX)  Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)  Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)  Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)  Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)  James Burges (Ex-Co-founder and Vice President of Innovation, OpenBiome)  Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)  JP Benya (Ex-Vice President, Operations, Assembly Biosciences)  Lee Jones (President and Chief Executive Officer, Rebiotix)  Mark Heiman (Ex-Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)  Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra) The report also includes detailed profiles of the companies (listed below) engaged in developing microbiome therapeutics, diagnostics and screening / profiling test; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.  4D Pharma  Biosotia Microbiomics  DNA Genotek  Finch Therapeutics  GoodGut  Infant Bacterial Therapeutics  Invivo Healthcare  MaaT Pharma  OxThera  Qu Biologics  Rebiotix  Seres Therapeutics  Servatus  Shoreline Biome For additional details, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis [more]
  • jameshebrew
  • The novel cardiovascular drug delivery devices market is projected to grow at a CAGR of 9.3%, till 2035, claims Roots Analysis Given the growing number of patients suffering from cardiovascular disorders and the high associated financial burden, cardiovascular drug eluting stents have emerged as a safe and efficient novel drug delivery device to assist in providing effectual treatment. Roots Analysis has announced the addition of “Novel Cardiovascular Drug Delivery Devices Market, 2022-2035” report to its list of offerings. In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; cardiovascular stents have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stents were used extensively to open the blocked passages and restore adequate blood flow to the heart. However, in recent years, a shift in preference has been observed towards the use of drug-eluting stents, which are coated with a polymer carrying an antiproliferative drug. Key Market Insights Over 90 cardiovascular drug eluting stents are presently available in this market space About 65% of these devices are coated with sirolimus drug, followed by those coated with everolimus and paclitaxel. Further, more than 70% of the stents are manufactured by using cobalt alloy. It is interesting to mention that stent length of more than 85% of the devices is in the range of 31 mm to 50 mm. ~40 players are currently be engaged in the production of cardiovascular drug eluting stents Majority of the players engaged in this domain are large firms (501-10,000 employees, 41%), followed by mid-sized players (51-500 employees, 26%), very large players (10,000+ employees, 18%) and small (2-50 employees, 15%) companies. Additionally, most of the service providers (38%) are based in Asia, followed by those having headquarters in Europe and North America. Over 70 novel therapeutics are being developed to target a wide range of cardiovascular diseases Majority (50%) of the therapies targeting cardiovascular disorder are currently in early stages of development (discovery and preclinical). It is also worth mentioning that over 65% of the drug candidates targeting cardiovascular diseases are gene therapies. More than 50 players are engaged in offering novel cardiovascular-based services / solutions Over 60% of the players offering such services / solutions are based in North America. It is interesting to mention that this domain is dominated (more than 40%) by the players offering digital therapeutics services. Till date, 900+ patents have been filed related to novel cardiovascular drug delivery devices In terms of the intellectual property developed across the world, the R&D activity is currently concentrated in North America and Europe. Further, most patented inventions are focused on the development of bioresorbable and biodegradable drug eluting stents. Global demand for novel cardiovascular drug delivery devices is anticipated to grow at a CAGR of over 13%, during 2022-2035 In 2035, sirolimus eluting stents are expected to contribute over 50% of the total demand for novel cardiovascular drug delivery devices, majority (~70%) of such devices are manufactured using cobalt chromium as a stent material. Players based in North America are anticipated to capture over 80% of the market share by 2035 The overall market of novel cardiovascular drug delivery devices is expected to be primarily driven by the rising demand for therapeutic interventions and recent technology advancements in the field. The estimates in our report suggest that stents manufactured using cobalt chromium are expected to hold more than 70% of the market share in 2035. It is interesting to mention that the market for stents manufactured using platinum chromium are expected to grow at a relatively faster pace (11.5%), during the forecast period. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/novel-cardiovascular-drug-delivery-devices-market/request-sample.html Key Questions Answered  Who are the leading players engaged in offering cardiovascular drug eluting stents?  Which type of drug eluting stent is most commonly offered by developers engaged in this market space?  What is the relative competitiveness of players engaged in the development / manufacturing of cardiovascular drug eluting stents?  How has the patent landscape in this domain evolved over the last two decades?  What is the present and likely future demand for cardiovascular drug eluting stents in the overall healthcare sector?  What are the anticipated future trends related to cardiovascular drug eluting stents market?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the novel cardiovascular drug delivery devices market has been analyzed across the following segments:  Type of Drug Eluted  Sirolimus  Paclitaxel  Everolimus  Zotarolimus  Others  Type of Stent Material  Cobalt Chromium  Platinum Chromium  Stainless Steel  Others  Key Geographical Regions  North America  Europe  Asia  Middle East and North Africa  Latin America  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.  Alvimedica  B. Braun  Boston Scientific  Cook Medical  Eurocor Scientific  Lepu Medical  Medtronic  Meril  Relisys  Sahajanand Medical Technologies For additional details, please visit https://www.rootsanalysis.com/reports/novel-cardiovascular-drug-delivery-devices-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • mattewwilson
  • Men have continually sought out approaches to growth their manhood. Men today use glide male enhancement capsules as tons as they use dietary dietary supplements. There aren't several pills that will increase the scale of your penis. For men who've micropenises, enlargement surgery isn't continually endorsed. Some permanent aspect outcomes may additionally arise once these surgical procedures. High-excellent sexual performance is what several men obtain. There are many supplements available that will help you acquire this intention. Few of these tablets are effective. These pills can't handiest growth a man's erection length, but they'll be additionally effective. These drugs conjointly will be used to boom the libido or sexual need of a person. Some guys attention on increasing the length and first-category of erectile operate, whilst others enhance testosterone stages. Young guys have problem obtaining erections. Several older men struggle to keep the equal level of erectile energy as their younger counterparts. Erectile disorder is a bother that young guys fancy as a nice deal as older ones. You are not the most effective one that wants to stay your sexual pastime going all night. Several men searching for out approaches to boost their sexual overall performance. You'll be able to improve your partner's sexual performance by wanting for brand new product or fixing current issues. There are many male supplements and pills available. But, there are straightforward ways that to seek out the nice. (AMAZING DISCOUNT) Get BioEnhance Male Enhancement For The Lowest Price Click Here https://fitnesdiet.com/bioenhance-male-enhancement/
  • jameshebrew
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. Key Questions Answered  Who are the leading players offering services for the development of companion diagnostics?  Which are the key geographies where companion diagnostics development service providers are located?  Which analytical techniques are used by the service providers engaged companion diagnostics development services market?  Who are the leading companion diagnostics developers?  Which biomarkers are most commonly targeted by the marketed products / investigational programs?  Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?  Which drug developers are most likely to partner with the service providers to seek their expertise?  What are the key value drivers of the merger and acquisition activity within companion diagnostics development services market?  Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:  Type of Service Offered  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Technique Used  NGS  PCR  ICH / ISH  Liquid Biopsy  Others  Therapeutic Areas  Oncological  Non-oncological  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:  Mike Klein (Chief Executive Officer, Genomenon)  Mark Kiel (Founder and Chief Scientific Officer, Genomenon)  Candace Chapman (Vice President of Marketing, Genomenon)  Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)  Paul Kortschak (Former Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive officer, OWL Metabolomics)  Lawrence Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories) The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.  Almac Diagnostic Services  BGI Genomics  Biocartis  Cerba Research  Geneuity Clinical Research Services  Interpace Biosciences  Labcorp (formerly known as Covance)  MEDICAL & BIOLOGICAL LABORATORIES (MBL)  MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)  MLM Medical Labs  Novogene  Q2 Solutions  Quest Diagnostics  ResearchDx For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
2 3 4 5 6 7 8 9 10 Next Last